We are live on ! Find out more
KRYS icon

Krystal Biotech
KRYS

90 hedge funds and large institutions have $502M invested in Krystal Biotech in 2020 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 35 increasing their positions, 28 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

25% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 28

17% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 12

0.49% more ownership

Funds ownership: 66.17% → 66.66% (+0.49%)

0% more funds holding

Funds holding: 90 → 90 (0)

21% less capital invested

Capital invested by funds: $635M → $502M (-$133M)

Holders
90
Holders Change
–
Holders Change %
0%
% of All Funds
1.98%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.04%
New
14
Increased
35
Reduced
28
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CCM
Consonance Capital Management
New York
+$23.6M
2
CS
Credit Suisse
Switzerland
+$15.7M
3
FCM
Farallon Capital Management
California
+$13.1M
4
CWG
C WorldWide Group
Denmark
+$7.1M
5
Aviva
Aviva
United Kingdom
+$4.86M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$55.1M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$8.25M
3
SFM
Sphera Funds Management
Israel
-$4.78M
4
BBA
Baker Bros. Advisors
New York
-$4.61M
5
PAMU
Pictet Asset Management (UK)
United Kingdom
-$3.33M
Name Holding Trade Value Shares
Change 		Change in
Stake
EI
26
EAM Investors
California
$3M +$207K +3,967 +6%
Charles Schwab
27
Charles Schwab
California
$2.98M +$80.5K +1,539 +2%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$2.82M -$124K -2,369 -4%
William Blair & Company
29
William Blair & Company
Illinois
$2.63M -$150K -2,873 -5%
SST
30
S Squared Technology
New York
$2.6M – – –
Citigroup
31
Citigroup
New York
$2.58M -$55.4K -1,060 -2%
AI
32
Atom Investors
Texas
$2.08M +$2.52M +48,201 New
JP Morgan Chase
33
JP Morgan Chase
New York
$2.02M +$1.41M +26,892 +136%
N
34
Nuveen
North Carolina
$1.8M +$114K +2,189 +6%
Invesco
35
Invesco
Georgia
$1.5M -$2.49M -47,632 -58%
AA
36
ALPS Advisors
Colorado
$1.36M -$176K -3,366 -10%
ACH
37
ArrowMark Colorado Holdings
Colorado
$1.32M – – –
EGI
38
EAM Global Investors
California
$1.3M -$262 -5 -0%
MOACM
39
Mutual of America Capital Management
New York
$1.22M -$64.9K -1,241 -4%
CIP
40
Chartwell Investment Partners
Pennsylvania
$1.11M +$153K +2,931 +13%
Neuberger Berman Group
41
Neuberger Berman Group
New York
$1.08M -$816K -15,600 -38%
MAM
42
Martingale Asset Management
Massachusetts
$1.07M +$1.3M +24,800 New
California Public Employees Retirement System
43
California Public Employees Retirement System
California
$1.01M -$1.75M -33,509 -59%
Swiss National Bank
44
Swiss National Bank
Switzerland
$943K +$15.7K +300 +1%
Allianz Asset Management
45
Allianz Asset Management
Germany
$937K -$501K -9,583 -31%
TD Asset Management
46
TD Asset Management
Ontario, Canada
$897K -$277K -5,300 -20%
PPA
47
Parametric Portfolio Associates
Washington
$815K -$148K -2,823 -13%
New York State Common Retirement Fund
48
New York State Common Retirement Fund
New York
$770K +$120K +2,301 +15%
UBS Group
49
UBS Group
Switzerland
$727K +$295K +5,636 +50%
State of Wisconsin Investment Board
50
State of Wisconsin Investment Board
Wisconsin
$700K +$162K +3,100 +24%
1
2
3 4 5

KRYS Hedge Fund Activity: Q1 2020 in Review

90 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q1 2020, worth a combined $502M — down 21% from $635M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new KRYS positions and 12 closed out — a net gain of 2 holders — while 35 added to existing stakes and 28 trimmed.

The largest buyer was Consonance Capital Management, adding an estimated $23.6M. The largest seller was OrbiMed, exiting entirely with an estimated $55.1M sold.

  • 90 institutional investors held Krystal Biotech (KRYS) as of Q1 2020, unchanged from Q4 2019.
  • Funds reported $502M of Krystal Biotech stock for Q1 2020, down 21% quarter-over-quarter.
  • 14 funds opened new Krystal Biotech positions in Q1 2020 and 12 closed out, a net change of +2 holders.
  • The largest Krystal Biotech buyer in Q1 2020 was Consonance Capital Management, an estimated $23.6M added.
  • The largest Krystal Biotech seller in Q1 2020 was OrbiMed, an estimated $55.1M sold.

Based on aggregated 13F filings for Q1 2020.